» Articles » PMID: 31444781

Prediction of Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus

Overview
Date 2019 Aug 25
PMID 31444781
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease associated with major obstetrical complications such as gestational loss, preterm delivery, fetal growth restriction (FGR) and preeclampsia. Published literature is not consensual regarding the main risk factors for each of these outcomes. Our goal with this study was to determine the most important predictors for each of the main adverse pregnancy outcomes in this population. We conducted a retrospective cohort study of unifetal pregnancies of women with the diagnosis of SLE followed in our unit between January 1994 and December 2016. We excluded elective terminations of pregnancy and cases lost to follow-up and we analyzed 157 pregnancies (128 women). Multiple logistic regression models for the outcomes gestational loss, preterm delivery, fetal growth restriction, and preeclampsia were built. Two-sided p-values of < 0.05 were used to determine statistical significance, and two-sided confidence intervals of 95% are reported. In our cohort, the main risk factors for gestational loss were maternal age and the presence of antiphospholipid antibodies. Lupic nephritis was predictive of a preterm delivery and preeclampsia. Renal involvement and lupus flares during pregnancy were risk factors for FGR. Overall, the main risk factor for an adverse pregnancy outcome were lupus flares during pregnancy. Despite optimal pregnancy monitoring, women with SLE are still at risk for adverse pregnancy outcomes. Risk stratification for each of these outcomes is crucial for an effective counselling and tailored monitoring.

Citing Articles

Prediction of pregnancy outcomes in women with systemic lupus erythematosus before pregnancy: Application of machine learning models.

Paydar K, Sheikhtaheri A Heliyon. 2025; 11(4):e42679.

PMID: 40040993 PMC: 11876896. DOI: 10.1016/j.heliyon.2025.e42679.


The conditions that patients with systemic lupus erythematosus should fulfill before pregnancy to optimize outcomes: a large-scale multicenter cohort study from China.

Zhang X, Liu L, Lin S, Duan X, Luo H, Wang Y Arthritis Res Ther. 2025; 27(1):31.

PMID: 39934898 PMC: 11818194. DOI: 10.1186/s13075-025-03497-9.


Effects of perinatal disease activity on offspring's growth in patients with systemic lupus erythematosus.

Wei Y, Zhu Y, Tang J, Li J, Wang Z, Jin Z Arch Med Sci. 2024; 20(4):1171-1179.

PMID: 39439694 PMC: 11493028. DOI: 10.5114/aoms/154929.


Construction and application of fetal loss risk model in systemic lupus erythematosus patients with mild disease severity.

Chen Y, Chen Y, Li B, Xu W, Lei P, Liu H BMC Pregnancy Childbirth. 2024; 24(1):497.

PMID: 39044159 PMC: 11264457. DOI: 10.1186/s12884-024-06679-6.


Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus.

Nakai T, Honda N, Soga E, Fukui S, Kitada A, Yokogawa N Arthritis Res Ther. 2024; 26(1):63.

PMID: 38459603 PMC: 10924338. DOI: 10.1186/s13075-024-03298-6.